QTTB · Insider Trading

Q32 Bio Inc. Common Stock

Every open-market purchase and sale reported by QTTB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Form 4 Filings
50
most recent
Open-Market Buys
2
code P
Sales
14
code S
Reporting Insiders
8
current holders
QTTB — Recent Form 4 Transactions (latest 2026-10-14)
FiledInsiderRole TypeSharesValue
2026-10-14 Shelia M. Violette Chief Scientific Officer Sell −917 −$7.63K
2026-10-14 Lee Kalowski CFO and President Sell −1,301 −$10.82K
2026-10-14 Jodie Pope Morrison CEO Sell −3,221 −$26.80K
2026-08-27 Shelia M. Violette Chief Scientific Officer Sell −2,798 −$46.33K
2026-08-27 Lee Kalowski CFO and President Sell −3,972 −$65.78K
2026-08-27 Jodie Pope Morrison CEO Sell −9,845 −$163.03K
2026-07-21 Mark T Iwicki Director A +10,826 deriv. —
2026-07-21 Isaac Manke Director A +10,826 deriv. —
2026-07-21 Sven Ante Lundberg Director A +10,826 deriv. —
2026-07-21 Arthur Tzianabos Director A +10,826 deriv. —
2026-07-21 David S. Grayzel Director A +10,826 deriv. —
2026-07-21 Mary Thistle Director A +10,826 deriv. —
2026-07-21 Kathleen Laporte Director A +10,826 deriv. —
2026-07-21 Diyong Xu Director A +10,826 deriv. —
2026-07-20 Jodie Pope Morrison CEO A +132,000 —
2026-07-20 Shelia M. Violette Chief Scientific Officer A +37,500 —
2026-07-20 Lee Kalowski CFO and President A +53,250 —
2026-07-02 Isaac Manke Director M +53,521 +$149.86K
2026-06-16 Kathleen Laporte Director A +9,810 deriv. —
2026-06-16 Mark T Iwicki Director A +9,810 deriv. —
2026-06-16 David S. Grayzel Director A +9,810 deriv. —
2026-06-16 Mary Thistle Director A +9,810 deriv. —
2026-06-16 Arthur Tzianabos Director A +9,810 deriv. —
2026-06-16 Isaac Manke Director A +9,810 deriv. —
2026-06-16 Diyong Xu Director A +9,810 deriv. —
2026-06-16 Sven Ante Lundberg Director A +9,810 deriv. —
2026-06-01 OrbiMed Genesis GP LLC Director Buy +1,875,000 +$15.00M
2026-06-01 Diyong Xu Director Buy +1,875,000 +$15.00M
2026-03-20 Jodie Pope Morrison CEO A +132,000 —
2026-03-20 Lee Kalowski CFO and President A +53,250 —
2026-03-20 Shelia M. Violette Chief Scientific Officer A +37,500 —
2026-02-27 Jodie Pope Morrison CEO Sell −9,896 −$44.67K
2026-02-27 Lee Kalowski CFO and President Sell −3,995 −$18.04K
2026-02-27 Shelia M. Violette Chief Scientific Officer Sell −2,815 −$12.71K
2026-01-30 Sven Ante Lundberg Director A +20,363 deriv. —
2026-01-30 David S. Grayzel Director A +16,363 deriv. —
2026-01-30 Kathleen Laporte Director A +23,272 deriv. —
2025-12-04 Jodie Pope Morrison CEO Sell −22,506 −$77.87K
2025-12-04 Lee Kalowski CFO and President Sell −9,072 −$31.40K
2025-10-27 Arthur Tzianabos Director A +53,521 deriv. —
2025-10-27 Mark T Iwicki Director A +53,521 deriv. —
2025-10-27 Sven Ante Lundberg Director A +53,521 deriv. —
2025-10-27 Kathleen Laporte Director A +53,521 deriv. —
2025-10-27 Mary Thistle Director A +53,521 deriv. —
2025-10-27 Diyong Xu Director A +53,521 deriv. —
2025-10-27 David S. Grayzel Director A +53,521 deriv. —
2025-10-27 Isaac Manke Director A +53,521 deriv. —
2025-08-28 Shelia M. Violette Chief Scientific Officer Sell −2,990 −$5.38K
2025-08-28 Lee Kalowski CFO and President Sell −4,240 −$7.64K
2025-08-28 Jodie Pope Morrison CEO Sell −10,494 −$18.90K
QTTB — Current Insider Holders
InsiderRole Shares HeldValue
OrbiMed Genesis GP LLC Director 625,000 $5.30M
Diyong Xu Director 625,000 $5.30M
Jodie Pope Morrison CEO 340,038 $2.88M
Shelia M. Violette Chief Scientific Officer 163,131 $1.38M
Lee Kalowski CFO and President 137,170 $1.16M
Isaac Manke Director 53,521 $453.86K
Jason Campagna Chief Medical Officer 37,500 $318.00K
Arthur Tzianabos Director 7,983 $67.70K
QTTB Insider Trading FAQ
Who are the insiders at QTTB?
8 officers, directors and 10%+ beneficial owners currently report holdings in QTTB via SEC Form 4.
Are QTTB insiders buying or selling?
Across the 50 most recent Form 4 filings for QTTB, 2 were open-market purchases (code P) and 14 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is QTTB insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent QTTB filing is dated 2026-10-14.
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the QTTB quote page; the site-wide leaderboard is on the insider transactions hub.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.